Sign in
ACHL Stock Price, Chart, Stats & News
Achilles Therapeutics plc
Save
60.83M
Market cap
–
Current P/E
–
Forward P/E
ACHL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.71% |
ROA | -43.15% |
ROE | -41.05% |
D/E | 0.03x |
Interest coverage ratio | – |
ACHL valuation
P/E | – |
P/S | – |
P/B | 0.42x |
P/CF | -1.22x |
P/FCF | -1.23x |
P/OCF | -1.22x |
PEG | 0.23x |
EV multiple | -2.67x |
About
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma.
Similar securities
Based on sector and market capitalization
Report issue